How Will the Market React to Citius Pharmaceuticals Inc (CTXR) Stock Getting a Bullish Rating

Overall market sentiment has been high on Citius Pharmaceuticals Inc (CTXR) stock lately. CTXR receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Citius Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CTXR!

See Full CTXR Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With CTXR Stock Today?

Citius Pharmaceuticals Inc (CTXR) stock is trading at $1.27 as of 9:59 AM on Thursday, Jan 19, a loss of -$0.03, or -2.31% from the previous closing price of $1.30. The stock has traded between $1.20 and $1.34 so far today. Volume today is 772,963 compared to average volume of 752,230.

More About Citius Pharmaceuticals Inc

Citius Pharmaceuticals, Inc. is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome. The company was founded in 2007 and is headquartered in Cranford, NJ Click Here to get the full Stock Report for Citius Pharmaceuticals Inc stock.